Evidence map›Paper›PMID 42732362›Full record

ArticleHemaSphere2026

Clonotypic characterization defines B-cell drivers of clonal expansion and intratumor heterogeneity in IgM monoclonal gammopathies.

David F Moreno, Ferran Nadeu, Marta Casado-Peláez, Caterina Mata, Ian Márquez-López, Marco A Fernández, Sergi Vaqué, Elena Medina, Helena Llobregat, Marta Garrote and 13 more

Abstract read
In one paragraph

Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

David F MorenoAmyloidosis and Myeloma Unit, Department of Hematology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain.ORCID https://orcid.org/0000-0002-1752-3081
Ferran NadeuInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) University of Barcelona Barcelona Spain.
Marta Casado-PeláezJosep Carreras Leukaemia Research Institute (IJC) University of Barcelona Barcelona Spain.
Caterina MataJosep Carreras Leukaemia Research Institute (IJC) University of Barcelona Barcelona Spain.
Ian Márquez-LópezInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) University of Barcelona Barcelona Spain.
Marco A FernándezClinical Flow Cytometry Facility, Biomedical Diagnostic Center Hospital Clínic de Barcelona.
Sergi VaquéInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) University of Barcelona Barcelona Spain.
Elena MedinaAmyloidosis and Myeloma Unit, Department of Hematology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain.
Helena LlobregatInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) University of Barcelona Barcelona Spain.
Marta GarroteHematopathology Unit, Department of Pathology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain.
Joan MañéInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) University of Barcelona Barcelona Spain.
Oriol CardúsInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) University of Barcelona Barcelona Spain.
Luis Gerardo Rodríguez-LobatoAmyloidosis and Myeloma Unit, Department of Hematology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain.
Anna de DanielAmyloidosis and Myeloma Unit, Department of Hematology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain.
María Teresa CibeiraAmyloidosis and Myeloma Unit, Department of Hematology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain.
Theo Gremen OliveiraFundação Pró-Sangue Hemocentro de São Paulo São Paulo Brazil.
Elizaveta KulaevaPrincess Máxima Centrum for Pediatric Oncology Utrecht The Netherlands.
Ester LozanoAmyloidosis and Myeloma Unit, Department of Hematology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain.
Dolors ColomerCentro de Investigación Biomédica en Red de Cáncer (CIBERONC) Madrid Spain.
Laura RosiñolAmyloidosis and Myeloma Unit, Department of Hematology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain.
Ruben van BoxtelPrincess Máxima Centrum for Pediatric Oncology Utrecht The Netherlands.
Manel EstellerCentro de Investigación Biomédica en Red de Cáncer (CIBERONC) Madrid Spain.
Carlos Fernández de LarreaAmyloidosis and Myeloma Unit, Department of Hematology Hospital Clínic de Barcelona, University of Barcelona Barcelona Spain.ORCID https://orcid.org/0000-0003-4930-9255

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Waldenström macroglobulinemia (WM) and IgM monoclonal gammopathy of undetermined significance (MGUS) share the same cell of origin but differ in clonal size. Compared with other B-cell neoplasms, the lymphoplasmacytic clone in WM can be rather small, limiting our understanding of clonal expansion. We applied an integrative approach using single-cell RNA with B-cell receptor (BCR) sequencing, the assay for transposase-accessible chromatin, and whole-genome sequencing to characterize the tumor clone in patients with IgM MGUS, smoldering WM (SWM), and symptomatic WM (WM). IgM MGUS and low- or intermediate-risk SWM harbored multiple B-cell clones compared to WM.

Identifiers

PMID42732362
PMCPMC13570779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.